The certificate published for this listing is Janoshik task 66207, batch EJ98516: 5.12 mg reported, 99.018% purity, analysed 27 May 2025. Verification key FGV3I3HYZ7KI. It is not a certificate for the blend. The product page is BPC-157.
Body Protection Compound 157 (BPC-157) is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has attracted substantial research interest due to its apparent ability to accelerate tissue healing across a wide range of injury types — from tendon and muscle to bone and gut lining.
Mechanism of Action
BPC-157 appears to exert its effects through several overlapping pathways. In tendon and muscle models, researchers have observed upregulation of growth hormone receptor expression, particularly in fibroblasts at injury sites. This may explain the accelerated collagen synthesis seen in preclinical studies.
Perhaps more notably, BPC-157 has been shown to promote angiogenesis — the formation of new blood vessels — which is a critical rate-limiting step in tissue regeneration. Studies in rodent models of Achilles tendon transection found significantly increased vascular density in BPC-157-treated groups compared to controls.
Gastrointestinal Protection
Much of the foundational BPC-157 research centres on gastrointestinal pathology. Its parent protein is naturally expressed in gastric mucosa, and exogenous BPC-157 has demonstrated protective effects against ethanol-induced ulceration, NSAID-induced gut damage, and inflammatory bowel models. The compound appears to modulate nitric oxide signalling and stabilise endothelial function in the gut vasculature.
Neurological and Systemic Effects
More recent rodent studies have explored BPC-157's role in dopamine and serotonin system modulation. In models of Parkinson's disease induced by 6-OHDA lesioning, BPC-157 administration was associated with reduced dopaminergic neuron loss. Separately, anxiolytic and antidepressant-like effects have been observed in forced swim and elevated plus-maze paradigms, though the mechanisms remain incompletely characterised.
Current Research Status
As of 2025, BPC-157 has not completed Phase II or III human clinical trials for any indication. The overwhelming majority of data originates from rodent studies. Extrapolating doses and effects to humans requires caution. Researchers typically note the compound's apparent lack of acute toxicity in animal models and its stability in gastric acid (enabling oral administration in some protocols) as reasons for continued investigational interest.
Key Takeaways
- Derived from gastric protective protein; active as a pentadecapeptide
- Promotes angiogenesis and collagen synthesis at injury sites
- Strong preclinical evidence for gastrointestinal mucosal protection
- Emerging neurological research; mechanisms still under investigation
- No completed human clinical trials — all data remains preclinical
This article is for educational and research purposes only. BPC-157 is not approved for human use. Consult a qualified healthcare professional before use.